Isabel M. Pinto

No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin (2005)

Mesquita, Bárbara, Veiga, Isabel, Pereira, Deolinda, Tavares, Ana, Pinto, Isabel M, Pinto, Carla, ...

Abstract Background The mechanisms of chemoresistance in ovarian cancer patients remain largely to be elucidated. Paclitaxel/cisplatin combination is the standard chemotherapeutic treatment for this...

No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin

Mesquita, Bárbara, Veiga, Isabel, Pereira, Deolinda, Tavares, Ana, Pinto, Isabel M, Pinto, Carla, ...

No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin

Mesquita, Bárbara, Veiga, Isabel, Pereira, Deolinda, Tavares, Ana, Pinto, Isabel M, Pinto, Carla, ...